Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in hiv-negative volunteers

Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2013, Pages 41-50

  Kakuda, Thomas N ^a   Van Solingen Ristea, Rodica ^b   Aharchi, Fatima ^b   De Smedt, Goedele ^b   Witek, James ^a   Nijs, Steven ^b   Vyncke, Veerle ^b   Hoetelmans, Richard M W ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Virco BVBA   (Belgium)

Author keywords

Clinical trials; Drug interactions; Etravirine; Fluconazole; HIV; Pharmacokinetics; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ETRAVIRINE; FLUCONAZOLE; VORICONAZOLE;

ABDOMINAL DISTENSION; ADULT; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLURRED VISION; CATHETER SITE REACTION; CHAPPED LIPS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTURIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OROPHARYNX PAIN; PANCREAS DISEASE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL IMPAIRMENT; VITAL SIGN; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; FEMALE; FLUCONAZOLE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES; YOUNG ADULT;

EID: 84877850489     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011433329     Document Type: Article

References (26)

1. Jimenez-Nacher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol . 2011;7(4):457-477.
2. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, doubleblind, placebo-controlled trial. Lancet . 2007;370(9581):29-38.
3. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial. Lancet . 2007;370(9581):39-48.
4. Katlama C, Haubrich R, Lalezari J, et al, for the DUET-1, DUET-2 Study Groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS . 2009;23(17):2289-2300.
5. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther . 2010;15(7):1045-1052.
6. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel nextgeneration nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother . 2004;48(12):4680-4686.
7. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis . 2009;49(9):1441-1449.
8. Nozza S, Galli L, Bigoloni A, et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr . 2011;56(4):e113-e115.
9. Imaz A, del Saz SV, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr . 2009;52(3):382-386.
10. Loutfy M, Ribera E, Florence E, et al. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother . 2009;64(6):1341-1344.
11. Schöller-Gyüre M, Kakuda TN, van Solingen-Ristea RM, et al. No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers. Paper presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA. Abstract P22.
12. Schöller-Gyüre M, Kakuda TN, Stevens T, et al. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5 + 1 cocktail. Paper presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Abstract A-955.
13. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the nonnucleoside reverse transcriptase inhibitor etravirine. Antivir Ther . 2010;15(6):817-829.
14. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet . 2011;50(1):25-39.
15. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy . 2008;28(5):614-645.
16. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis . 2006;43:S28-S39.
17. Nivoix Y, Levêque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet . 2008;47(12): 779-792.
18. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIVnegative volunteers. Antivir Ther . 2007;12(5):789-796.
19. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf . 2010;9(1):125-137.
20. Vfend [summary of product characteristics]. http://www.emea. europa.eu/humandocs/PDFs/EPAR/vfend/emea-combined-h387en .pdf
21. Cohen CJ, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS . 2009;23(3):423-426.
22. Kakuda TN, Schler-Gye M, Workman C, et al. Single-and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther . 2008;13(5):655-661.
23. Kakuda TN, Wade JR, Snoeck E, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther . 2010;88(5):695-703.
24. Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady state pharmacokinetics of voriconazole. Br J Clin Pharmacol . 2003;56(suppl 1):51-55.
25. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol . 2003;56(suppl 1):56-61.
26. Andrews E, Damle BD, Fang A, et al. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol . 2008;65(4):531-539.